Hillevax IPO Presentation Deck
April 2022, 24 slides
  1. Hillevax
  2. Related Decks
  3. IPO Presentation Decks
presentation | Hillevax
disclaimer | Hillevax
offering overview | Hillevax
clinical demonstrated phase field efficacy seasoned leadership team world class vaccine | Hillevax
senior leadership | Hillevax
board of directors | Hillevax
crossover financing closed august perceptive advisors a a associates | Hillevax
for the prevention of related illness formerly bivalent vaccine potential to be first vaccine approved for related illness licensed from clinical demonstrated in adult phase study | Hillevax
is the most common cause of acute gastroenteritis in us and | Hillevax
global annual burden is high resulting in direct and indirect costs of in us and globally | Hillevax
and genotypes comprise the majority of infections a | Hillevax
a genotypes and virus like particles adjuvant | Hillevax
large clinical program demonstrates immunogenicity efficacy and safety tolerability | Hillevax
we believe that clinical data have substantially risked the program key clinical accomplishments adjuvant selection safety tolerability profile | Hillevax
clinical profile comparable to commercial vaccines | Hillevax
a blocking response following vaccination with against interim data from ongoing long ape nor gest | Hillevax
| Hillevax
we intend to focus our initial development primarily on the infant advantages of studying in infants endemic pattern of infection | Hillevax
phase pediatric study planned start | Hillevax
planned development and regulatory strategy focused on infant population followed by and or efficacy studies in older adults clinical program and recommendations establish efficacy in infants and bridge to older populations | Hillevax
and shingles as | Hillevax
potential billion dollar commercial opportunity | Hillevax
strong anticipated milestones | Hillevax
significant unmet medical need clinical demonstrated in adults excellent safety profile large potential commercial opportunity seasoned leadership team | Hillevax
See More
Hillevax
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Vaccine
Clinical development
Related decks
Valneva
IPO
April 2021
RenovoRx
IPO
August 2021
GreenLight
SPAC
August 2021
Hillstream BioPharma
Investor Presentation
July 2023
AbCellera
Results
November 2022
Blue Water Vaccines
Results
October 2022
BenevolentAI
Investor Presentation
October 2022
Alkermes
Investor Day
March 2021
Valneva
IPO
April 2021
RenovoRx
IPO
August 2021
GreenLight
SPAC
August 2021
Hillstream BioPharma
Investor Presentation
July 2023
AbCellera
Results
November 2022
Blue Water Vaccines
Results
October 2022
BenevolentAI
Investor Presentation
October 2022
Alkermes
Investor Day
March 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io